Compare Abeona Therapeutics Inc (ABEO) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs IAC/Interactivecorp — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while IAC/Interactivecorp trades at $40.21 (market cap $3.03B). The key difference: IAC/Interactivecorp is far larger — about 7.1× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, IAC/Interactivecorp nearer its low. Which is the better fit depends on your goals.
| ABEO | PPLI | |
|---|---|---|
Market Cap | $424.33M | $3.03B |
Sector | Health | Media |
52-Week High | $7.45 | $47.62 |
52-Week Low | $4.17 | $31.52 |
Enterprise Value | $279.23M | $3.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
People Incorporated (PPLI) trades at $41.58, down 3.17% amid bearish technical signals despite strong Q2 2026 earnings beat. The company shows mixed fundamentals with attractive valuation ratios (P/E 7.04, P/B 0.61) but volatile profitability trends. Recent news highlights digital revenue growth, corporate restructuring, and MGM investment gains, while institutional activity shows mixed positioning with Amundi increasing stake by 397.4% in Q2 2026.
PPLI presents a value opportunity with deep discount to analyst consensus target of $60.50 (45% upside), though investors face execution risks from restructuring and inconsistent earnings history. The stock's near-term direction hinges on successful asset monetization and sustained digital growth against backdrop of negative cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
